FFA-Induced Hypertension and Endothelial Dysfunction

Emory University

Status: Completed

Conditions: Hypertension; Endothelial Dysfunction

Treatments: Drug: Intralipid 20% @ 20cc/hour; Drug: Normal Saline; Dietary Supplement: 64-gram oral fat load; Dietary Supplement: 32-gram oral fat load; Drug: Intralipid 20%@ 40cc/hour

Study type: Interventional

Funder types: Other

Identifiers

NCT00589888

IRB00041116

IRB 668-2006 (Other Identifier)

Details and patient eligibility

About

The study is a prospective open label study to examine the effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. Subjects will receive either 8-hour of intravenous or oral fat loads in either low or high doses or normal saline in random order. Blood samples are drawn and vitals are measured before and after the infusions. Endothelial function and plasma glucose and lipid levels are measured to study the effects.

Full description

Insulin resistance has been implicated as the central mechanism in the development of several cardiovascular risk factors including hypertension, diabetes, lipid disorders, and coagulation disorders. Recent evidence suggests that increased levels of a circulation fat (free fatty acids or FFAs) are a leading candidate causing insulin resistance. Our preliminary studies in indicate that, in addition to insulin resistance, the infusion of Intralipid and heparin to increase FFAs resulted in a significant rise in systolic and diastolic blood pressure, impaired endothelial (vascular) function, and increased inflammatory markers in obese African Americans with and without diabetes. The effects of FFA on insulin action are well established; however, the blood pressure and vascular effects of FFAs infusion in obese subjects have not been fully investigated. We hypothesize that observed changes in blood pressure are the result of acute endothelial dysfunction, and/or increased activation of the autonomic nervous system. No previous studies have attempted to determine a dose response effect of increasing FFA on blood pressure. In addition, it is not know if increased FFAs by repeated oral fat load results in similar blood pressure than intravenous lipid infusion. Accordingly, we propose: 1) a systematic evaluation of the effects of increasing FFA levels on blood pressure and endothelial (vascular) function, and 2) determine the effects of comparable increases in FFA concentration via intravenous infusion of Intralipid or by repeated oral fat load on blood pressure, insulin resistance and endothelial dysfunction in obese subjects.

A group of obese normotensive subjects will be admitted to the Grady Clinical Research Center or to the Outpatient Research Unit in the Grady Diabetes Clinic on five occasions. In four of these admissions, research subjects will receive an 8-hour intravenous infusion, in random order, of increasing Intralipid concentration (10 ml, 20 ml, 40 ml per hour) or normal saline (40 ml per hour). During the final admission, research subjects will receive an oral liquid fat diet every 2 hours for 8-hours. The effect of increased FFAs on blood pressure and endothelial (vascular) function via intravenous infusion and via oral fat load therapy will be assessed.

Enrollment: 13 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males or females between the ages of 18 and 65 years.
• Definition: obese = BMI ≥ 30 kg/m2
• Blood pressure < 140/80 mm Hg and no prior history of hypertension

Exclusion criteria

• History of hypertension or previous history of antihypertensive drug therapy.
• Current tobacco use
• Fasting triglyceride levels > 250 mg/dL during the stabilization period.
• Liver disease (ALT 2.5x > upper limit of normal), or other significant medical or surgical illness, including myocardial ischemia, congestive heart failure, liver failure, and infectious processes.
• Serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for females.
• History of drug or alcohol abuse within the last 5 years.
• Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
• Female subjects are pregnant or breast feeding at time of enrollment into the study.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

13 participants in 5 patient groups, including a placebo group

Intralipid 20%@ 20cc/hour

Active Comparator group

Description:

Intralipid 20% IV infusion at 20cc/hour

Treatment:

Drug: Intralipid 20% @ 20cc/hour

Intralipid 20% @ 40cc/hour

Active Comparator group

Description:

Intralipid 20% IV infusion at 40cc/hour

Treatment:

Drug: Intralipid 20%@ 40cc/hour

Normal Saline infusion @ 40cc/hour

Placebo Comparator group

Description:

Normal Saline continuous IV infusion at 40cc/hour for 8 hours

Treatment:

Drug: Normal Saline

32-gram oral fat load

Active Comparator group

Description:

32-gram oral fat load once

Treatment:

Dietary Supplement: 32-gram oral fat load

64-gram oral fat load

Active Comparator group

Description:

64-gram oral fat load once

Treatment:

Dietary Supplement: 64-gram oral fat load